{
  "meta": {
    "description": "Scientifically corrected oncology knowledge graph with accurate gene-drug-pathway relationships",
    "version": "2.0",
    "last_updated": "2025-10-24"
  },
  "nodes": [
    {
      "id": "disease:Lung Cancer",
      "label": "Lung Cancer",
      "type": "disease",
      "color": "#9b5de5",
      "properties": {
        "aliases": ["lung", "NSCLC", "SCLC", "non-small cell lung cancer", "small cell lung cancer"],
        "description": "Malignant tumor of the lung tissue, including NSCLC and SCLC subtypes"
      }
    },
    {
      "id": "disease:Breast Cancer",
      "label": "Breast Cancer",
      "type": "disease",
      "color": "#9b5de5",
      "properties": {
        "aliases": ["breast", "invasive ductal carcinoma", "invasive lobular carcinoma"],
        "description": "Malignant tumor originating in breast tissue"
      }
    },
    {
      "id": "disease:Colorectal Cancer",
      "label": "Colorectal Cancer",
      "type": "disease",
      "color": "#9b5de5",
      "properties": {
        "aliases": ["colorectal", "colon cancer", "rectal cancer", "CRC"],
        "description": "Cancer that develops in the colon or rectum, often starting from adenomatous polyps"
      }
    },
    {
      "id": "disease:Pancreatic Cancer",
      "label": "Pancreatic Cancer",
      "type": "disease",
      "color": "#9b5de5",
      "properties": {
        "aliases": ["pancreatic", "PDAC", "pancreatic adenocarcinoma"],
        "description": "Aggressive cancer of the pancreas with poor prognosis, mostly adenocarcinoma"
      }
    },
    {
      "id": "disease:Prostate Cancer",
      "label": "Prostate Cancer",
      "type": "disease",
      "color": "#9b5de5",
      "properties": {
        "aliases": ["prostate", "PCa", "adenocarcinoma of prostate"],
        "description": "Cancer of the prostate gland in men, usually adenocarcinoma"
      }
    },
    {
      "id": "disease:Melanoma",
      "label": "Melanoma",
      "type": "disease",
      "color": "#9b5de5",
      "properties": {
        "aliases": ["malignant melanoma", "cutaneous melanoma"],
        "description": "Aggressive form of skin cancer originating from melanocytes"
      }
    },
    {
      "id": "disease:Ovarian Cancer",
      "label": "Ovarian Cancer",
      "type": "disease",
      "color": "#9b5de5",
      "properties": {
        "aliases": ["ovarian", "epithelial ovarian cancer", "serous ovarian carcinoma"],
        "description": "Cancer that begins in the ovaries, predominantly epithelial type"
      }
    },
    {
      "id": "gene:EGFR",
      "label": "EGFR",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "Epidermal Growth Factor Receptor",
        "function": "Transmembrane glycoprotein receptor tyrosine kinase that binds EGF family ligands, leading to dimerization, autophosphorylation, and activation of downstream signaling pathways including PI3K/AKT and RAS/MAPK. Mutations common in lung cancer.",
        "chromosome": "7p12",
        "aliases": ["ERBB1", "HER1"]
      }
    },
    {
      "id": "gene:KRAS",
      "label": "KRAS",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "KRAS Proto-Oncogene",
        "function": "GTPase that regulates cell proliferation and differentiation through RAS/MAPK pathway. G12C mutation is targetable in lung cancer. Most commonly mutated oncogene in cancer.",
        "chromosome": "12p12.1",
        "aliases": ["Kirsten RAS"]
      }
    },
    {
      "id": "gene:ALK",
      "label": "ALK",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "Anaplastic Lymphoma Kinase",
        "function": "Receptor tyrosine kinase. EML4-ALK fusion in lung cancer creates constitutively active kinase driving oncogenesis. Target for ALK inhibitors.",
        "chromosome": "2p23.2"
      }
    },
    {
      "id": "gene:BRAF",
      "label": "BRAF",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "B-Raf Proto-Oncogene",
        "function": "Serine/threonine kinase in RAS/MAPK pathway. V600E mutation (90% of BRAF mutations) leads to constitutive activation. Common in melanoma.",
        "chromosome": "7q34",
        "aliases": ["B-RAF1"]
      }
    },
    {
      "id": "gene:MET",
      "label": "MET",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "MET Proto-Oncogene",
        "function": "Receptor tyrosine kinase for hepatocyte growth factor (HGF). MET exon 14 skipping mutations create therapeutic target. Involved in cellular migration and invasion.",
        "chromosome": "7q31.2",
        "aliases": ["HGFR"]
      }
    },
    {
      "id": "gene:ERBB2",
      "label": "ERBB2",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "Erb-B2 Receptor Tyrosine Kinase 2",
        "function": "Member of EGFR family. No direct ligand binding but forms heterodimers with other ERBB family members. Amplification/overexpression in breast cancer. Target for trastuzumab and other HER2-targeted therapies.",
        "chromosome": "17q12",
        "aliases": ["HER2", "NEU"]
      }
    },
    {
      "id": "gene:PIK3CA",
      "label": "PIK3CA",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha",
        "function": "Catalytic subunit of PI3K. H1047R and E545K hotspot mutations lead to PI3K pathway activation. Targetable with PI3K inhibitors like alpelisib.",
        "chromosome": "3q26.32"
      }
    },
    {
      "id": "gene:TP53",
      "label": "TP53",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "Tumor Protein P53",
        "function": "Tumor suppressor protein that responds to cellular stress by inducing cell cycle arrest, apoptosis, or senescence. Mutated in >50% of cancers. Guardian of the genome.",
        "chromosome": "17p13.1",
        "aliases": ["P53"]
      }
    },
    {
      "id": "gene:BRCA1",
      "label": "BRCA1",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "BRCA1 DNA Repair Associated",
        "function": "Tumor suppressor involved in homologous recombination DNA repair. Germline mutations predispose to breast and ovarian cancer. BRCA1/2 mutations create synthetic lethality with PARP inhibition.",
        "chromosome": "17q21.31"
      }
    },
    {
      "id": "gene:BRCA2",
      "label": "BRCA2",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "BRCA2 DNA Repair Associated",
        "function": "Tumor suppressor essential for homologous recombination repair. Contains BRC motifs that interact with RAD51. Mutations predispose to breast, ovarian, pancreatic, and prostate cancers.",
        "chromosome": "13q13.1"
      }
    },
    {
      "id": "gene:PTEN",
      "label": "PTEN",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "Phosphatase and Tensin Homolog",
        "function": "Tumor suppressor phosphatase that dephosphorylates PIP3, negatively regulating PI3K/AKT pathway. Loss leads to AKT activation and cellular proliferation.",
        "chromosome": "10q23.31"
      }
    },
    {
      "id": "gene:RB1",
      "label": "RB1",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "RB Transcriptional Corepressor 1",
        "function": "Tumor suppressor that controls G1/S checkpoint by sequestering E2F transcription factors. Phosphorylation by CDK4/6-cyclin D complexes inactivates RB1.",
        "chromosome": "13q14.2",
        "aliases": ["Rb"]
      }
    },
    {
      "id": "gene:MYC",
      "label": "MYC",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "MYC Proto-Oncogene",
        "function": "Transcription factor that forms heterodimers with MAX to regulate genes involved in cell cycle progression, metabolism, and apoptosis. Frequently amplified in cancers.",
        "chromosome": "8q24.21",
        "aliases": ["c-MYC"]
      }
    },
    {
      "id": "gene:APC",
      "label": "APC",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "APC Regulator of WNT Signaling Pathway",
        "function": "Tumor suppressor that regulates Wnt signaling by promoting Î²-catenin degradation. Mutations in >80% of colorectal cancers, leading to Wnt pathway activation.",
        "chromosome": "5q22.2"
      }
    },
    {
      "id": "gene:MLH1",
      "label": "MLH1",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "MutL Homolog 1",
        "function": "DNA mismatch repair protein. Loss leads to microsatellite instability (MSI). MSI-high tumors are responsive to immunotherapy.",
        "chromosome": "3p22.2"
      }
    },
    {
      "id": "gene:CDKN2A",
      "label": "CDKN2A",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "Cyclin Dependent Kinase Inhibitor 2A",
        "function": "Encodes p16INK4A and p14ARF tumor suppressors. p16 inhibits CDK4/6, p14ARF stabilizes p53. Frequently deleted in melanoma and other cancers.",
        "chromosome": "9p21.3",
        "aliases": ["p16", "CDKN2", "INK4A"]
      }
    },
    {
      "id": "gene:AR",
      "label": "AR",
      "type": "gene",
      "color": "#e63946",
      "properties": {
        "full_name": "Androgen Receptor",
        "function": "Nuclear hormone receptor activated by testosterone and DHT. Drives prostate cancer growth. Target for antiandrogens like enzalutamide.",
        "chromosome": "Xq12"
      }
    },
    {
      "id": "protein:PD-L1",
      "label": "PD-L1",
      "type": "protein",
      "color": "#ff6b6b",
      "properties": {
        "full_name": "Programmed Death-Ligand 1",
        "function": "Immune checkpoint protein expressed on tumor cells and immune cells. Binds PD-1 receptor to suppress T-cell activation. Target for immunotherapy.",
        "gene": "CD274"
      }
    },
    {
      "id": "protein:VEGF",
      "label": "VEGF",
      "type": "protein",
      "color": "#ff6b6b",
      "properties": {
        "full_name": "Vascular Endothelial Growth Factor",
        "function": "Growth factor that promotes angiogenesis. Target for bevacizumab in cancer therapy.",
        "gene": "VEGFA"
      }
    },
    {
      "id": "protein:PARP",
      "label": "PARP",
      "type": "protein",
      "color": "#ff6b6b",
      "properties": {
        "full_name": "Poly (ADP-Ribose) Polymerase",
        "function": "DNA repair enzyme involved in base excision repair. PARP inhibition creates synthetic lethality in BRCA-deficient tumors.",
        "gene": "PARP1"
      }
    },
    {
      "id": "pathway:PI3K-AKT-mTOR",
      "label": "PI3K-AKT-mTOR Pathway",
      "type": "pathway",
      "color": "#2a9d8f",
      "properties": {
        "description": "Critical pathway regulating cell survival, proliferation, and metabolism. Activated by growth factor receptors, negatively regulated by PTEN."
      }
    },
    {
      "id": "pathway:RAS-MAPK",
      "label": "RAS-MAPK Pathway",
      "type": "pathway",
      "color": "#2a9d8f",
      "properties": {
        "description": "Pathway controlling cell proliferation and differentiation. Activated by receptor tyrosine kinases through RAS-RAF-MEK-ERK cascade."
      }
    },
    {
      "id": "pathway:EGFR Signaling",
      "label": "EGFR Signaling",
      "type": "pathway",
      "color": "#2a9d8f",
      "properties": {
        "description": "Growth factor receptor signaling activating both PI3K-AKT and RAS-MAPK pathways upon ligand binding and receptor dimerization."
      }
    },
    {
      "id": "pathway:p53 Pathway",
      "label": "p53 Pathway",
      "type": "pathway",
      "color": "#2a9d8f",
      "properties": {
        "description": "Tumor suppressor pathway responding to DNA damage and cellular stress through cell cycle arrest, apoptosis, or senescence."
      }
    },
    {
      "id": "pathway:Wnt Signaling",
      "label": "Wnt Signaling",
      "type": "pathway",
      "color": "#2a9d8f",
      "properties": {
        "description": "Developmental pathway regulating cell fate and proliferation. Dysregulated in colorectal cancer through APC mutations."
      }
    },
    {
      "id": "pathway:DNA Repair",
      "label": "Homologous Recombination Repair",
      "type": "pathway",
      "color": "#2a9d8f",
      "properties": {
        "description": "High-fidelity DNA double-strand break repair mechanism. Defects in BRCA1/2 create dependency on alternative repair pathways."
      }
    },
    {
      "id": "pathway:Cell Cycle Control",
      "label": "Cell Cycle Control",
      "type": "pathway",
      "color": "#2a9d8f",
      "properties": {
        "description": "Regulatory mechanisms controlling cell division through checkpoints, particularly G1/S transition via RB-E2F pathway."
      }
    },
    {
      "id": "pathway:Immune Checkpoint",
      "label": "PD-1/PD-L1 Immune Checkpoint",
      "type": "pathway",
      "color": "#2a9d8f",
      "properties": {
        "description": "Immune regulatory pathway where PD-L1 on tumor cells binds PD-1 on T-cells to suppress immune response."
      }
    },
    {
      "id": "drug:Osimertinib",
      "label": "Osimertinib",
      "type": "drug",
      "color": "#f4a261",
      "properties": {
        "mechanism": "Third-generation irreversible EGFR tyrosine kinase inhibitor targeting T790M resistance mutation",
        "target": "EGFR",
        "indication": "EGFR-mutant NSCLC"
      }
    },
    {
      "id": "drug:Trastuzumab",
      "label": "Trastuzumab",
      "type": "drug",
      "color": "#f4a261",
      "properties": {
        "mechanism": "Monoclonal antibody targeting HER2 extracellular domain, blocking signaling and inducing ADCC",
        "target": "HER2/ERBB2",
        "indication": "HER2-positive breast cancer"
      }
    },
    {
      "id": "drug:Pembrolizumab",
      "label": "Pembrolizumab",
      "type": "drug",
      "color": "#f4a261",
      "properties": {
        "mechanism": "Monoclonal antibody blocking PD-1 receptor on T-cells, preventing PD-L1 binding",
        "target": "PD-1 receptor",
        "indication": "Various cancers with PD-L1 expression or MSI-high"
      }
    },
    {
      "id": "drug:Olaparib",
      "label": "Olaparib",
      "type": "drug",
      "color": "#f4a261",
      "properties": {
        "mechanism": "PARP inhibitor creating synthetic lethality in BRCA-deficient tumors by preventing single-strand break repair",
        "target": "PARP enzyme",
        "indication": "BRCA-mutant breast/ovarian cancer"
      }
    },
    {
      "id": "drug:Bevacizumab",
      "label": "Bevacizumab",
      "type": "drug",
      "color": "#f4a261",
      "properties": {
        "mechanism": "Monoclonal antibody neutralizing VEGF, preventing angiogenesis",
        "target": "VEGF protein",
        "indication": "Various solid tumors"
      }
    },
    {
      "id": "drug:Sotorasib",
      "label": "Sotorasib",
      "type": "drug",
      "color": "#f4a261",
      "properties": {
        "mechanism": "Covalent inhibitor specifically targeting KRAS G12C mutation",
        "target": "KRAS G12C",
        "indication": "KRAS G12C-mutant NSCLC"
      }
    },
    {
      "id": "drug:Crizotinib",
      "label": "Crizotinib",
      "type": "drug",
      "color": "#f4a261",
      "properties": {
        "mechanism": "Multi-kinase inhibitor targeting ALK, ROS1, and MET",
        "target": "ALK/ROS1/MET",
        "indication": "ALK-rearranged or ROS1-rearranged NSCLC"
      }
    },
    {
      "id": "drug:Palbociclib",
      "label": "Palbociclib",
      "type": "drug",
      "color": "#f4a261",
      "properties": {
        "mechanism": "Selective CDK4/6 inhibitor blocking RB phosphorylation and G1/S transition",
        "target": "CDK4/6",
        "indication": "HR-positive breast cancer"
      }
    },
    {
      "id": "biomarker:EGFR Mutation",
      "label": "EGFR Mutation",
      "type": "biomarker",
      "color": "#4361ee",
      "properties": {
        "biomarker_type": "Predictive",
        "description": "Activating mutations (L858R, exon 19 deletions) predict response to EGFR inhibitors"
      }
    },
    {
      "id": "biomarker:KRAS G12C",
      "label": "KRAS G12C",
      "type": "biomarker",
      "color": "#4361ee",
      "properties": {
        "biomarker_type": "Predictive",
        "description": "Specific KRAS mutation targetable by sotorasib and adagrasib"
      }
    },
    {
      "id": "biomarker:HER2 Amplification",
      "label": "HER2 Amplification",
      "type": "biomarker",
      "color": "#4361ee",
      "properties": {
        "biomarker_type": "Predictive",
        "description": "ERBB2 gene amplification/protein overexpression predicting response to HER2-targeted therapy"
      }
    },
    {
      "id": "biomarker:BRCA Mutation",
      "label": "BRCA Mutation",
      "type": "biomarker",
      "color": "#4361ee",
      "properties": {
        "biomarker_type": "Predictive",
        "description": "Germline or somatic BRCA1/2 mutations predicting PARP inhibitor sensitivity"
      }
    },
    {
      "id": "biomarker:PD-L1 Expression",
      "label": "PD-L1 Expression",
      "type": "biomarker",
      "color": "#4361ee",
      "properties": {
        "biomarker_type": "Predictive",
        "description": "PD-L1 protein expression by IHC predicting immunotherapy response"
      }
    },
    {
      "id": "biomarker:MSI-High",
      "label": "MSI-High",
      "type": "biomarker",
      "color": "#4361ee",
      "properties": {
        "biomarker_type": "Predictive",
        "description": "Microsatellite instability from mismatch repair deficiency, highly predictive of immunotherapy response"
      }
    }
  ],
  "edges": [
    {
      "source": "gene:EGFR",
      "target": "pathway:EGFR Signaling",
      "relation": "participates_in",
      "properties": {"strength": "primary"}
    },
    {
      "source": "pathway:EGFR Signaling",
      "target": "pathway:PI3K-AKT-mTOR",
      "relation": "activates",
      "properties": {}
    },
    {
      "source": "pathway:EGFR Signaling",
      "target": "pathway:RAS-MAPK",
      "relation": "activates",
      "properties": {}
    },
    {
      "source": "gene:KRAS",
      "target": "pathway:RAS-MAPK",
      "relation": "participates_in",
      "properties": {"strength": "primary"}
    },
    {
      "source": "gene:BRAF",
      "target": "pathway:RAS-MAPK",
      "relation": "participates_in",
      "properties": {}
    },
    {
      "source": "gene:PIK3CA",
      "target": "pathway:PI3K-AKT-mTOR",
      "relation": "participates_in",
      "properties": {"strength": "primary"}
    },
    {
      "source": "gene:PTEN",
      "target": "pathway:PI3K-AKT-mTOR",
      "relation": "inhibits",
      "properties": {}
    },
    {
      "source": "gene:TP53",
      "target": "pathway:p53 Pathway",
      "relation": "participates_in",
      "properties": {"strength": "primary"}
    },
    {
      "source": "gene:BRCA1",
      "target": "pathway:DNA Repair",
      "relation": "participates_in",
      "properties": {}
    },
    {
      "source": "gene:BRCA2",
      "target": "pathway:DNA Repair",
      "relation": "participates_in",
      "properties": {}
    },
    {
      "source": "gene:APC",
      "target": "pathway:Wnt Signaling",
      "relation": "inhibits",
      "properties": {}
    },
    {
      "source": "gene:RB1",
      "target": "pathway:Cell Cycle Control",
      "relation": "participates_in",
      "properties": {}
    },
    {
      "source": "protein:PD-L1",
      "target": "pathway:Immune Checkpoint",
      "relation": "participates_in",
      "properties": {}
    },
    {
      "source": "drug:Osimertinib",
      "target": "gene:EGFR",
      "relation": "inhibits",
      "properties": {"mechanism": "irreversible_binding"}
    },
    {
      "source": "drug:Trastuzumab",
      "target": "gene:ERBB2",
      "relation": "inhibits",
      "properties": {"mechanism": "antibody_binding"}
    },
    {
      "source": "drug:Pembrolizumab",
      "target": "pathway:Immune Checkpoint",
      "relation": "blocks",
      "properties": {"mechanism": "PD-1_blockade"}
    },
    {
      "source": "drug:Olaparib",
      "target": "protein:PARP",
      "relation": "inhibits",
      "properties": {"mechanism": "synthetic_lethality"}
    },
    {
      "source": "drug:Bevacizumab",
      "target": "protein:VEGF",
      "relation": "neutralizes",
      "properties": {"mechanism": "antibody_binding"}
    },
    {
      "source": "drug:Sotorasib",
      "target": "gene:KRAS",
      "relation": "inhibits",
      "properties": {"mechanism": "G12C_specific"}
    },
    {
      "source": "drug:Crizotinib",
      "target": "gene:ALK",
      "relation": "inhibits",
      "properties": {}
    },
    {
      "source": "drug:Palbociclib",
      "target": "pathway:Cell Cycle Control",
      "relation": "inhibits",
      "properties": {"mechanism": "CDK4_6_inhibition"}
    },
    {
      "source": "pathway:PI3K-AKT-mTOR",
      "target": "disease:Lung Cancer",
      "relation": "associated_with", 
      "properties": {}
    },
    {
      "source": "pathway:PI3K-AKT-mTOR",
      "target": "disease:Breast Cancer",
      "relation": "associated_with",
      "properties": {}
    },
    {
      "source": "pathway:RAS-MAPK",
      "target": "disease:Lung Cancer",
      "relation": "associated_with",
      "properties": {}
    },
    {
      "source": "pathway:RAS-MAPK",
      "target": "disease:Melanoma",
      "relation": "associated_with",
      "properties": {}
    },
    {
      "source": "pathway:RAS-MAPK",
      "target": "disease:Colorectal Cancer",
      "relation": "associated_with",
      "properties": {}
    },
    {
      "source": "pathway:Wnt Signaling",
      "target": "disease:Colorectal Cancer",
      "relation": "associated_with",
      "properties": {}
    },
    {
      "source": "pathway:DNA Repair",
      "target": "disease:Breast Cancer",
      "relation": "associated_with",
      "properties": {}
    },
    {
      "source": "pathway:DNA Repair",
      "target": "disease:Ovarian Cancer",
      "relation": "associated_with",
      "properties": {}
    },
    {
      "source": "biomarker:EGFR Mutation",
      "target": "disease:Lung Cancer",
      "relation": "indicates",
      "properties": {}
    },
    {
      "source": "biomarker:KRAS G12C",
      "target": "disease:Lung Cancer",
      "relation": "indicates",
      "properties": {}
    },
    {
      "source": "biomarker:HER2 Amplification",
      "target": "disease:Breast Cancer",
      "relation": "indicates",
      "properties": {}
    },
    {
      "source": "biomarker:BRCA Mutation",
      "target": "disease:Breast Cancer",
      "relation": "indicates",
      "properties": {}
    },
    {
      "source": "biomarker:BRCA Mutation",
      "target": "disease:Ovarian Cancer",
      "relation": "indicates",
      "properties": {}
    },
    {
      "source": "biomarker:PD-L1 Expression",
      "target": "disease:Lung Cancer",
      "relation": "indicates",
      "properties": {}
    },
    {
      "source": "biomarker:MSI-High",
      "target": "disease:Colorectal Cancer",
      "relation": "indicates",
      "properties": {}
    },
    {
      "source": "drug:Osimertinib",
      "target": "disease:Lung Cancer",
      "relation": "indicated_for",
      "properties": {"context": "EGFR_mutant"}
    },
    {
      "source": "drug:Trastuzumab",
      "target": "disease:Breast Cancer",
      "relation": "indicated_for",
      "properties": {"context": "HER2_positive"}
    },
    {
      "source": "drug:Pembrolizumab",
      "target": "disease:Lung Cancer",
      "relation": "indicated_for",
      "properties": {"context": "PD-L1_positive"}
    },
    {
      "source": "drug:Olaparib",
      "target": "disease:Breast Cancer",
      "relation": "indicated_for",
      "properties": {"context": "BRCA_mutant"}
    },
    {
      "source": "drug:Olaparib",
      "target": "disease:Ovarian Cancer",
      "relation": "indicated_for",
      "properties": {"context": "BRCA_mutant"}
    },
    {
      "source": "drug:Sotorasib",
      "target": "disease:Lung Cancer",
      "relation": "indicated_for",
      "properties": {"context": "KRAS_G12C"}
    },
    {
      "source": "drug:Palbociclib",
      "target": "disease:Breast Cancer",
      "relation": "indicated_for",
      "properties": {"context": "HR_positive"}
    }
  ]
}